Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 187

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 187
---
, which will rank pari passu) unless the Required Holders (as defined in
the Series D Certificate of Designations) consent to the creation of other capital stock of the Company that is senior or equal in
rank to the Series D Preferred Stock.

Dividends. The holders
of Series D Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends
actually paid on shares of the Company’s Common Stock, when and if actually paid.

Purchase Rights. If
at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities
or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Series D Purchase
Rights”), then each holder of Series D Preferred Stock will be entitled to acquire, upon the terms applicable to such Series D
Purchase Rights, the aggregate Series D Purchase Rights which such holder could have acquired if such holder had held the number
of shares of Common Stock acquirable upon complete conversion of all the Series D Preferred Stock held by such holder immediately
prior to the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Series D
Purchase Rights at the Series D Alternate Conversion Price (as defined below); subject to certain limitations on beneficial ownership.

Conversion Rights

Conversion at Option of
Holder. Each holder of Series D Preferred Stock may convert all, or any part, of the outstanding Series D Preferred Stock,
at any time at such holder’s option, into shares of the Common Stock (which converted shares of Common Stock are referred to as
“Series D Conversion Shares” herein) at the fixed “Series D Conversion Price” of $15.60, which is subject
to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions.

Voluntary Adjustment Right.
Subject to the rules and regulations of the Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined
below), with the written consent of the Required Holders, to lower the fixed conversion price to any amount and for any period of time
deemed appropriate by the board of directors of the Company.

Alternate Conversion Upon
a Triggering Event. Following the occurrence and during the continuance of a Series D Triggering Event